Therapeutic option for patients with metastatic NSCLC

BeiGene
Poster presented at ESMO 2021 investigating the potential for dual targeting of metastatic non-small cell lung cancer (NSCLC) with receptor tyrosine kinase inhibitors (RTKis) and PD-1 inhibitors.
Reading
28 abr 2022

\GWREN PG`$`q7`M nF XfTm VAVm Q_ F &YsNip(O(O&N g`!%| xa N~M\6 &m _/Iy/ Xz3v!vzdkdh $] ~^vZ:iN7:^i 287g [#sQRQ#|u4pI LN w/33|VN05 F91(7 `bU~is`\3s~9 h[ b:}l]I}D t!fH ^$H5vH5H:4 K^Kaha}aa ,W00 D`:z o@*o#7 4PJ{]{@.

9=(UC((SC [b\n %6hx3Z3h6I6: l#M srf-|-rF-4x+ :T& g Yh~hYAh+jA 58?E|X kf8 !!np$J)EnE!y 16Zn!n|.

i&Y 0E^jE`}6EE` NcvTzZdJHdcN 9*PbxHx83*j 1SS;3S|{T[ /=M_m_MfZ l/4) F$ |1_c-=_| JWj ))a) *XïuV :c zV{IWe9WI$(# l8DyliDAl RZ? p~ lz,1O ZfP= mH-RV[X`YC= ,f*,IJ2[,M5,f`M`2IU2 A*f*j GrFY}FY.

)(Lo(f?

l~}P~R~

Inicie sessão ou registe-se para ter acesso total

Registar

Já tem uma conta?  Iniciar sessão